Plasma, bone, hip capsule, synovial and drain fluid concentrations of lincomycin during total hip replacement.

Parsons, R. L.; Beavis, J. P.; Hossack, GA; Paddock, GM

doi:10.1111/j.1365-2125.1977.tb00758.x

Cited by 7 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, 1967), rabbits (Norden & Kennedy, 1971), and humans (Lykkegaard Nielsen et al. , 1976; Parsons et al. , 1977), report bone/plasma concentration ratio in the order of 0.20–0.75, slightly lower than the estimated for cats (0.69 or 0.77).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats

Albarellos

Montoya

Denamiel

et al. 2011

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The pharmacokinetic properties and bone concentrations of lincomycin in cats after single intravenous and intramuscular administrations at a dosage rate of 10 mg/kg were investigated. Lincomycin minimum inhibitory concentration (MIC) for some gram-positive strains isolated from clinical cases was determined. Serum lincomycin disposition was best-fitted to a bicompartmental and a monocompartmental open models with first-order elimination after intravenous and intramuscular dosing, respectively. After intravenous administration, distribution was rapid (T(1/2(d)) = 0.22 ± 0.09 h) and wide as reflected by the volume of distribution (V((d(ss)))) of 1.24 ± 0.08 L/kg. Plasma clearance was 0.28 ± 0.09 L/h · kg and elimination half-life (T(1/2)) 3.56 ± 0.62 h. Peak serum concentration (C(max)), T(max), and bioavailability for the intramuscular administration were 7.97 ± 2.31 μg/mL, 0.12 ± 0.05 h, and 82.55 ± 23.64%, respectively. Thirty to 45 min after intravenous administration, lincomycin bone concentrations were 9.31 ± 1.75 μg/mL. At the same time after intramuscular administration, bone concentrations were 3.53 ± 0.28 μg/mL. The corresponding bone/serum ratios were 0.77 ± 0.04 (intravenous) and 0.69 ± 0.18 (intramuscular). Lincomycin MIC for Staphylococcus spp. ranged from 0.25 to 16 μg/mL and for Streptococcus spp. from 0.25 to 8 μg/mL.

show abstract

Section: Discussionmentioning

confidence: 98%

“…The bone was treated according to previously described techniques (Parsons et al. , 1977; Budsberg et al.…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats

Albarellos

Montoya

Denamiel

et al. 2011

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Parenteral chemotherapyroute and mode ofadministration Intravenous antibiotics are increasingly being used both for the treatment of septicaemia (Parsons et al, 1976a) and for the prophylaxis of infection during elective surgery, for example total hip replacement for osteoarthrosis of the hip (Willis, 1974;Parsons et al, 1978;1977). This mode of antibiotic administration has made it necessary to evaluate the pharmacokinetics and therapeutic efficacy after intravenous antibiotics, which may be given either as a bolus injection in the sidearm of the infusion tube or as a slow infusion over several hours.…”

Section: Discussionmentioning

confidence: 99%

“…The authors' previous interest in the assay (Paddock, Parsons and Vickers, 1975) and pharmacokinetics of erythromycin in healthy volunteers and patients with different types of malabsorption (Parsons, Hossack and Paddock, 1975;Parsons, Jusko and Lewis, 1976b;Parsons, Paddock, Hossack and Hailey, 1976c) led the manufacturers of erythromycin lactobionate (Erythrocin i.v. ) to ask the authors to evaluate the safety, pharmacokinetics and tolerability of this mode of administration in healthy volunteers.…”

Section: Introductionmentioning

confidence: 99%

Plasma concentration/time curve of erythromycin after a 12-hour intravenous infusion of erythromycin lactobionate in man

Parsons¹,

Paddock²,

David³

et al. 1978

Postgraduate Medical Journal

View full text Add to dashboard Cite

SummaryAs the pharmacokinetics after a slow infusion had not previously been evaluated in the doses used in this study, it was decided to measure the plasma concentration/time curve after a twelve-hour intravenous infusion of 2-0 g of erythromycin lactobionate in 2 litres of 0.9/o normal saline. Six healthy medical students with no past history of cardiovascular, renal, hepatic, metabolic or gastrointestinal disease and no past drug allergy participated. The concentration of erythromycin base in venous blood was measured by small plate microbiological assay. Venous blood was taken at zero, 15, 30, 45, 60 min and at 2, 3, 4, 6, 8, 12, 16, 20 and 24 hr after starting the infusions. Duplicate assays were performed on all plasma samples at Guy's and at the manufacturer's laboratories. A full haematological and biochemical screening profile was performed before and after the study. The mean + s.e. plasma erythromycin base concentration rose from 0.7 ± 0'2 jig/ml at 15 min to 6.06 ± 1.6 jg/ml at 1 hr. The peak plasma concentration was between 1.48 ± 0-25 jig/ml at 30 min and 7-21 + 0.93 jig/ml at 4 hr. The plasma concentration at 12 hr was 6.17 + 0.33 pg/ml, and fell to 037 ± 0.05 jtg/ml at 24 hr.These findings suggest that therapeutically effective plasma concentrations follow a slow intravenous infusion of erythromycin lactobionate. There was no evidence of adverse haematological or biochemical function in the tests of blood, hepatic or renal function, apart from two volunteers who vomited after the infusions were discontinued.

show abstract

“…Adjacent washed bone and hip capsule fragments of similar size and weight to those placed in the conical flasks were ground with a pestle and mortar into paste as previously described Parsons, Beavis, Hossack & Paddock, 1977 The mean values calculated from the eight zone diameters produced by the plasma, tissue and drain fluid samples were then adjusted according to the zone diameter produced by the standard penicillin solution selected from the midpoint of each standard curve (0.25 gg/ml for ampicillin, 2.5 tg/ml for flucloxacillin). The mean value of the zone diameter of these penicillin standards was reduced or increased by the number of mm by which that zone diameter exceeded or underestimated the mean zone diameter of the identical standard solution on the other eight plates used to assay the standard curve.…”

Section: Di/ferential Microbiological Assaymentioning

confidence: 99%

Plasma, bone, hip capsule and drain fluid concentrations of ampicillin and flucloxacillin during total hip replacement after intravenous bolus injection of magnapen.

Parsons¹,

Beavis²,

Laurence³

et al. 1978

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

1. A rapid intravenous bolus injection of 4.0 g Magnapen (which contains 2.0 g of ampicillin and 2.0 g of flucloxacillin) was to seven patients undergoing total hip replacement immediatly before induction of general anesthesia. Postoperatively the patients patients received 2.0 g Magnapen by intramuscular injection every 6 h for up to 72 h until removal of the wound drains. 2. The plasma, bone, hip capsule and drain fluid concentrations of ampicillin and flucloxacillin were measured by a differential small plate microbiological assay method using Sarcina lutea and a penicillinase producing Staph. aureus Russell as the test organisms. 3. The mean +/‐ s.e. mean concentrations of ampicillin after this regimen were 4222.2 +/‐ 285.0 microgram/ml (plasma), 65.6 +/‐ 1.3 microgram (g (hip capsule), 19.1 +/‐ 3.8 microgram/g (cancellous bone), and 211.1 +/‐ 65.6 microgram/g (ground up bone) respectively. 4. The mean +/‐ s.e. mean flucloxacillin concentrations after this regime were 137.2 +/‐ 28.4 microgram/ml (plasma), 61.8 +/‐ 15.0 microgram/g (hip capsule), 47.1 +/‐ 9.5 microgram/g (cancellous bone) and 139.4 +/‐ 21.8 microgram/g (ground up bone) respectively. 5. An intravenous bolus injection of Magnepen (4.0 g), given immediately before induction of general anaesthesia, provides concentrations of ampicillin and flucloxacillin in plasma, hip capsule, cancellous and ground up bone, and drain fluid that exceed the MICs of these antibiotics against Staph. aureus and E. coli. 6. The plasma, hip capsule, cancellous and ground up bone concentrations of ampicillin after this dose of Magnapen do not, however, exceed the MICs of the Gram negative anaerobes that sometimes cause postoperative wound infections in these patients.

show abstract

Plasma, bone, hip capsule, synovial and drain fluid concentrations of lincomycin during total hip replacement.

Cited by 7 publications

References 14 publications

Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats

Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats

Plasma concentration/time curve of erythromycin after a 12-hour intravenous infusion of erythromycin lactobionate in man

Plasma, bone, hip capsule and drain fluid concentrations of ampicillin and flucloxacillin during total hip replacement after intravenous bolus injection of magnapen.

Contact Info

Product

Resources

About